

Aurinia Pharmaceuticals Inc. completes US\$191.7 million public offering

Date closed: 12/12/2019

Value: US\$191.7 million

On December 12, 2019, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (Aurinia or the Company) announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters' option to purchase additional common shares (the Offering). The shares were sold at a public offering price of US\$15.00 per share. The gross offering proceeds to the Company from this Offering are approximately US\$191.7 million, before deducting underwriting discounts and commissions and other estimated offering expenses.

Jefferies LLC and SVB Leerink LLC acted as joint book-running managers for the Offering. H.C. Wainwright & Co. LLC, Oppenheimer & Co. Inc., and Bloom Burton Securities Inc. acted as co-managers for the Offering.

Aurinia, headquartered in Vancouver, British Columbia, is a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications.

BLG represented Aurinia with a team led by Stephen Robertson that included Kent Kufeldt, Michelle Wilkinson, Lauren DeGoey, Connor MacLeod (securities), Kim Maguire and Robert Biggar (Tax).